D2M Biotherapeutics United States

A human-genetics driven next generation immunity-oncology company
Nan Bing
CEO 
Functionality

D3 BIO

Website:
www.d3bio.com
Partnering Objectives
Biotech/Pharma Category
Dr John Jin
Dr John Jin
Co-founder & CBO 
Functionality
John Jin
Co-founder&CBO 

Dao Tun GmbH Switzerland

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

Dr. Tianke Wang
Dr. Tianke Wang
CEO 
Functionality

DHVC United States

Life Science and Healthcare Venture Capital Investor
Website:
www.dh.vc
Company Size (Fulltime employees)
Year of foundation
2013
Partnering Objectives
Please specify your partnering goal
Investment
Headquartner in China
Medtech Development Stage
Ali Farahanchi
Managing Director 
Functionality

Duality Biologics China

Duality Biologics is a China biotech company focusing on the discovery, development and commercialization of new modality biologics to provide solutions to unmet medical needs for grievous diseases in Great China area. Backed by proprietary new modality platform ensuring fast biological validation and development, Duality Biologics has been building a combined pipeline of First-in-class and Best-in-class. Currently, Duality seeks for licensing-in opportunities in broad disease areas especially oncology and autoimmune diseases
Website:
N/A
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Clinical stage assets in oncology and immunology
Headquartner in China
Dr. John Zhu
Founder and CEO 
Functionality

Elasmogen Ltd United Kingdom

Elasmogen, a next generation biologics company, develops soloMERs which are high affinity binding, single-domains; they are small (9% of an antibody), highly stable proteins and crucially are outside the complex/competitive antibody patent landscape. soloMERs are pre-disposed to generating potent neutralisers by binding to novel or cryptic epitopes. Their small size makes them ideal for both site-specific delivery and penetration of solid tumours. Our lead product, ADCP165, is an anti-ROR1 soloMER drug conjugate being co-developed with Almac Discovery. This program is tracking for entry into the clinic 2022/3 with follow on products in the pipeline. In addition our lead anti-auto-immune inflammatory domain, ELN/22, a tetravalent, bi-paratopic anti-TNF product is being developed for oral delivery for the treatment of IBD.
We are currently looking for partners for our existing assets and also companies who would like to access our powerful, patent protected soloMER platform to develop new products.
Company Size (Fulltime employees)
Year of foundation
2016
Please specify your partnering goal
Licensing of existing assets and co-development of new therapeutic development
Headquartner in China
Dr. Caroline Barelle
CEO 

gaotejia investment China

healthcare investment
Website:
www.szgig.com
Partnering Objectives
Headquartner in China
shaojie Zhang
associate 

GCV Life India

Life science-focused Innovation licensing organizations looking to commercialize global innovations for the Indian and South Asian markets through a unique partnership-led model.
Dr. Chirag Jain
Analyst 
Functionality

GIG China

GIG, one of the leading healthcare investment institute, was founded in Shenzhen in 2001. AUM is RMB ¥20b. It has invested in 80+ healthcare companies. 22 went IPO. GIG has 90+ staff in team with operating offices in Shenzhen, Shanghai, Beijing, Nanjing and Hongkong.

Website:
www.szgig.com
Company Size (Fulltime employees)
Please specify your partnering goal
potential investing targets and collaborations
Headquartner in China
Medtech Development Stage
Denise Chen
Partner 
Functionality

Hangzhou Angine Biotech Co., Ltd. China

Angine Biotech (Angine) is a international business development solution provider company dedicated in the pharma, biotech and medical device fields for the global business partnership building. We are working with our overseas' business partner to introduce the clinical and market unmet projects/products to China by leveraging the local expertise and resources. 

With the professional international BD team, the expert consultant group as well as the valuable data room for Chinese markets in the biotech and health care field, Angine is committed to provide the tailor-made solutions for the overseas’ partners who would like to explore the access to the Chinese markets. The solutions are including but not limited to the Chinese market landscape investigation, the regulatory affairs support, the reimbursement policy study, the ideal incubator and strategic biz partner recommendation, as well as the capital and talent services when the project is confirmed to settle in the referred incubator or campus.

Angine would like work with you as a strategic partner to co-develop the Chinese healthcare market, to make your ideas or IP become the products by inputting the expertise from both sides.

You can write an email to leoluo@anginebio.com for your ideas and proposals for the Chinese markets. Let our team give you a solution.

Leo Luo
LinkedIn logo Managing Director